乳腺癌中的免疫检查点抑制剂：一篇叙述性综述。
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review.
作者信息
Nunes Filho Paulo, Albuquerque Caroline, Pilon Capella Mariana, Debiasi Marcio
机构信息
Labcorp Drug Development, Burlington, NC, USA.
Rua Augusto Pestana, 25/92, Porto Alegre, RS, Brazil.
出版信息
Oncol Ther. 2023 Jun;11(2):171-183. doi: 10.1007/s40487-023-00224-9. Epub 2023 Mar 14.
Abstract
Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer's prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.
摘要
乳腺癌是全球患者中最常被诊断出的恶性肿瘤，也是癌症相关死亡的主要原因。尽管转移性乳腺癌仍无法治愈，但在过去10年中，由于引入了新的靶向药物，如免疫检查点抑制剂（ICI），其预后已得到显著改善。然而，这些药物会引发独特的副作用，即免疫介导的不良事件（irAE）。在本文中，我们回顾了ICI在转移性以及新辅助/辅助治疗环境下用于乳腺癌治疗的临床证据，随后回顾了最常见的irAE以及用于治疗它们的药物。我们认为，任何治疗乳腺癌患者的癌症专科医生都应了解这些副作用以便早期发现和处理，肿瘤学家应成为负责处理这些副作用的多学科团队的领导者。
相似文献
1
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review.乳腺癌中的免疫检查点抑制剂：一篇叙述性综述。
Oncol Ther. 2023 Jun;11(2):171-183. doi: 10.1007/s40487-023-00224-9. Epub 2023 Mar 14.
2
Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.癌症患者接受免疫检查点抑制剂治疗的特定免疫相关不良事件的真实世界临床和经济结局。
Oncologist. 2021 Nov;26(11):e2002-e2012. doi: 10.1002/onco.13918. Epub 2021 Aug 24.
3
Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗肝细胞癌患者的免疫相关不良事件与预后的相关性。
Front Immunol. 2021 Dec 7;12:794099. doi: 10.3389/fimmu.2021.794099. eCollection 2021.
4
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
5
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.免疫相关不良事件作为免疫检查点抑制剂治疗转移性肾细胞癌患者的临床生物标志物。
Oncologist. 2021 Oct;26(10):e1742-e1750. doi: 10.1002/onco.13868. Epub 2021 Jul 8.
6
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗转移性肾和尿路上皮癌患者的条件性免疫毒性发生率。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000371.
7
Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma.辅助免疫检查点抑制剂治疗 III 期可切除黑色素瘤患者的内分泌和肝脏免疫相关不良事件的非典型表现和处理。
JCO Oncol Pract. 2020 Feb;16(2_suppl):10s-14s. doi: 10.1200/JOP.19.00649.
8
The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.免疫相关不良事件在 PD-1/PD-L1 抑制剂中的报告不一致且不充分：一项随机对照临床试验的系统评价。
Oncologist. 2021 Dec;26(12):e2239-e2246. doi: 10.1002/onco.13940. Epub 2021 Aug 31.
9
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.免疫检查点抑制剂相关原发性肾上腺功能不全：WHO VigiBase 报告分析。
Oncologist. 2020 Aug;25(8):696-701. doi: 10.1634/theoncologist.2019-0555. Epub 2020 May 17.
10
Hematological immune related adverse events after treatment with immune checkpoint inhibitors.免疫检查点抑制剂治疗后的血液学免疫相关不良事件。
Eur J Cancer. 2021 Apr;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Epub 2021 Mar 9.
引用本文的文献
1
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.释放免疫检查点抑制剂在激素受体阳性/人表皮生长因子受体2阴性乳腺癌中的潜力：一项系统综述。
Cancers (Basel). 2025 Sep 8;17(17):2940. doi: 10.3390/cancers17172940.
2
Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.乳腺癌肿瘤治疗中皮肤及口腔黏膜副作用的治疗策略：一项综述
Biomedicines. 2025 Aug 4;13(8):1901. doi: 10.3390/biomedicines13081901.
3
Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer.乳腺癌中免疫检查点抑制剂反应和耐药的生物标志物。
Breast. 2025 Jul 21;83:104545. doi: 10.1016/j.breast.2025.104545.
4
Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients.表达髓过氧化物酶的肿瘤相关中性粒细胞与转移性乳腺癌患者的预后较差相关。
Sci Rep. 2025 Jul 12;15(1):25270. doi: 10.1038/s41598-025-08854-x.
5
Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model.使用4T1小鼠模型研究PD-L1上调对三阴性乳腺癌免疫检查点抑制剂疗效的影响。
Int J Oncol. 2025 Jul;67(1). doi: 10.3892/ijo.2025.5760. Epub 2025 Jun 13.
6
Role of Immunotherapy in Conjunction With the Surgical Treatment of Breast Cancer: Preoperative and Postoperative Applications.免疫疗法联合乳腺癌手术治疗的作用：术前和术后应用
Cureus. 2024 Oct 14;16(10):e71441. doi: 10.7759/cureus.71441. eCollection 2024 Oct.
7
Advancements in Immunotherapy for Breast Cancer: Mechanisms, Efficacy, and Future Directions.乳腺癌免疫治疗的进展：机制、疗效及未来方向。
Cureus. 2024 Aug 31;16(8):e68351. doi: 10.7759/cureus.68351. eCollection 2024 Aug.
8
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.接受新辅助化疗免疫治疗的早期乳腺癌患者乳腺MRI上的区域淋巴结变化
Breast Cancer Res Treat. 2025 Jan;209(1):147-159. doi: 10.1007/s10549-024-07481-w. Epub 2024 Sep 21.
9
The Proapoptotic Action of Pyrrolidinedione-Thiazolidinone Hybrids towards Human Breast Carcinoma Cells Does Not Depend on Their Genotype.吡咯烷二酮-噻唑烷酮杂化物对人乳腺癌细胞的促凋亡作用不依赖于其基因型。
Cancers (Basel). 2024 Aug 22;16(16):2924. doi: 10.3390/cancers16162924.
10
Breast Cancer and Therapy-Related Cardiovascular Toxicity.乳腺癌与治疗相关的心血管毒性
J Breast Cancer. 2024 Jun;27(3):147-162. doi: 10.4048/jbc.2024.0085. Epub 2024 Apr 29.
本文引用的文献
1
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.抗 TGF-β/PD-L1 双特异性抗体促进 T 细胞浸润，并在三阴性乳腺癌中表现出增强的抗肿瘤活性。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005543.
2
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.抗 PD-1 治疗的黑色素瘤患者临床应答和免疫相关不良事件的肠道微生物组特征
Nat Med. 2022 Mar;28(3):545-556. doi: 10.1038/s41591-022-01698-2. Epub 2022 Feb 28.
3
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.三阴性、早期高危及局部晚期乳腺癌新辅助治疗（无论是否联合阿替利珠单抗）的病理完全缓解（pCR）：NeoTRIP米开朗基罗随机研究
Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17.
4
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.癌症临床试验中接受免疫治疗、靶向治疗或化疗的患者发生严重不良事件的风险的性别差异。
J Clin Oncol. 2022 May 1;40(13):1474-1486. doi: 10.1200/JCO.21.02377. Epub 2022 Feb 4.
5
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events.预测、诊断和治疗免疫相关不良事件的事实和希望。
Clin Cancer Res. 2022 Apr 1;28(7):1250-1257. doi: 10.1158/1078-0432.CCR-21-1240.
6
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
7
Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer.两例转移性肾细胞癌患者停用纳武利尤单抗后出现免疫相关不良事件延迟发作的病例。
IJU Case Rep. 2021 Jun 28;4(5):326-329. doi: 10.1002/iju5.12338. eCollection 2021 Sep.
8
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
9
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.帕博利珠单抗对比研究者选择化疗用于转移性三阴性乳腺癌（KEYNOTE-119）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4.
10
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.YM101：一种同时靶向 TGF-β和 PD-L1 的双特异性抗体的构建、表达及增强的抗肿瘤活性。
J Hematol Oncol. 2021 Feb 16;14(1):27. doi: 10.1186/s13045-021-01045-x.
Zotero 插件